Comparative Pharmacology
Head-to-head clinical analysis: THEOBID versus TORNALATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THEOBID versus TORNALATE.
THEOBID vs TORNALATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing cAMP, and blocking adenosine receptors. It also has anti-inflammatory and immunomodulatory effects.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
Theophylline extended-release capsules: 300-600 mg/day orally divided every 12 hours. Initial dose 300 mg/day, titrate based on serum concentrations (target 10-20 mcg/mL). Max 600 mg/day unless serum levels monitored.
2 puffs (340 mcg) inhaled via oral inhalation 4 times daily; maximum 12 puffs/day.
None Documented
None Documented
Neonates: 24-36 h; Children (1-9 y): 3-4 h; Adults (non-smokers): 6-12 h; Adults (smokers): 4-5 h; Hepatic cirrhosis: prolonged (up to 30 h); Heart failure: prolonged (up to 20 h).
Terminal elimination half-life is approximately 9-12 hours in healthy adults. May be prolonged in elderly or those with hepatic impairment, necessitating dose adjustment.
Renal (10% unchanged), hepatic metabolism (90%, primarily via CYP1A2 and CYP3A4); 20% excreted in feces as metabolites.
Primarily renal excretion of unchanged drug and metabolites; <10% fecal. Approximately 60-70% of a dose is recovered in urine as unchanged drug and glucuronide conjugates within 24 hours.
Category C
Category C
Bronchodilator
Bronchodilator